BD Hypak™ Glass Prefillable Syringe for Anticoagulant
BD tools for anticoagulant combination product developers
- Overview
- BD Expertise
- Availability
- Resources
BD HypakTM Glass Prefillable Syringe (PFS) for Anticoagulant is a tool for anticoagulant combination product developers. It is the most commonly used PFS in the world1 and enables the delivery of injectable anti-coagulants through subcutaneous route of delivery. BD HypakTM Glass Prefillable Syringe for Anticoagulant is compatible with the BD PreventisTM Needle Shielding System2 and comes with technical documentation and support. Samples are available on demand.
BD HypakTM Glass Prefillable Syringe for Anticoagulant Features
- Plunger Rod: different colors available for customization
- Cut flange: prevents rolling
- Needle cap: protect the needle
- Glass container: 1ml format
- Staked needle: ready to use, no needle connection required
BD HypakTM Glass Prefillable Syringe for Anticoagulant Benefits
- Enabler of the delivery of injectable anti-coagulants through subcutaneous route of delivery
- The most commonly used PFS in the world1
- Multi-sourcing network for business continuity
- Comes with technical documentation and support
- Compatible with the BD PreventisTM Needle Shielding System2
- BD analysis, based on TMC study, IQVIA data [internal analysis]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2022
- Stack-up analysis, SD20190231 rev3.0, [Internal report], Pont-de-Claix, FR: Becton Dickinson and Company
Our expertise in BD HypakTM Glass Prefillable Syringe for Anticoagulant
- Build on years of experience with the BD HypakTM Glass Prefillable Syringe
- The original PFS for low molecular weight heparins (LMWH) since launch1,3,4,5
- Supplies the majority of the LMWH market worldwide1,3,4
- World class manufacturing capabilities: BD is uniquely positioned with high volume production capacity6
- BD analysis, based on TMC study, IQVIA data [internal analysis]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2022
- Stack-up analysis, SD20190231 rev3.0, [Internal report], Pont-de-Claix, FR: Becton Dickinson and Company
- BD analysis, [internal report]. Pont-de-Claix, FR: Becton, Dickinson and Company; 2022
- Lovenox, USPI, Apr 2022
- Aspen, General presentation, Accessed 19 /05 /2022; 2021
- BD-PS external communication to customers - BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity Over Next Four Years. https://news.bd.com/2020-12-02-BD-to-Invest-1-2-Billion-in-Pre-Fillable-Syringe-Manufacturing-Capacity-Over-Next-Four-Years. Accessed Dec. 2, 2020
- Samples available on demand
- Commercial availability to be evaluated against requirements
View collected literature about BD offerings and our industry for information you can use to continue striving for excellence.